Allen Investment Management’s AbbVie ABBV Stock Holding History

Allen Investment Management’s Portfolio ABBV Stock Details ABBV Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$3.52M	Sell	13,993 -75	-0.5%	-$16.1K	0.04%	115
2026 Q1	$3.06M	Buy	14,068 +75	+0.5%	+$16.6K	0.04%	113
2025 Q4	$3.2M	Buy	13,993 +5,933	+74%	+$1.35M	0.04%	110
2025 Q3	$1.87M	Hold	8,060	–	–	0.02%	118
2025 Q2	$1.5M	Hold	8,060	–	–	0.02%	120
2025 Q1	$1.69M	Hold	8,060	–	–	0.02%	120
2024 Q4	$1.43M	Hold	8,060	–	–	0.02%	124
2024 Q3	$1.59M	Hold	8,060	–	–	0.02%	120
2024 Q2	$1.38M	Sell	8,060 -35	-0.4%	-$5.8K	0.02%	127
2024 Q1	$1.47M	Hold	8,095	–	–	0.02%	114
2023 Q4	$1.25M	Hold	8,095	–	–	0.02%	123
2023 Q3	$1.21M	Buy	8,095 +60	+0.7%	+$8.81K	0.02%	121
2023 Q2	$1.08M	Hold	8,035	–	–	0.02%	124
2023 Q1	$1.28M	Hold	8,035	–	–	0.02%	120
2022 Q4	$1.3M	Sell	8,035 -247	-3%	-$37.9K	0.02%	113
2022 Q3	$1.11M	Hold	8,282	–	–	0.02%	121
2022 Q2	$1.27M	Hold	8,282	–	–	0.02%	120
2022 Q1	$1.34M	Hold	8,282	–	–	0.02%	124
2021 Q4	$1.12M	Hold	8,282	–	–	0.01%	140
2021 Q3	$893K	Hold	8,282	–	–	0.01%	121
2021 Q2	$933K	Hold	8,282	–	–	0.01%	115
2021 Q1	$896K	Sell	8,282 -1,207	-13%	-$129K	0.01%	118
2020 Q4	$1.02M	Buy	9,489 +846	+10%	+$81.3K	0.02%	108
2020 Q3	$757K	Buy	8,643 +396	+5%	+$37.3K	0.01%	111
2020 Q2	$810K	Hold	8,247	–	–	0.02%	109
2020 Q1	$628K	Buy	8,247 +247	+3%	+$21K	0.02%	115
2019 Q4	$708K	Hold	8,000	–	–	0.02%	114
2019 Q3	$606K	Sell	8,000 -487	-6%	-$33.4K	0.02%	129
2019 Q2	$617K	Sell	8,487 -217	-2%	-$17.1K	0.02%	129
2019 Q1	$701K	Hold	8,704	–	–	0.02%	119
2018 Q4	$802K	Buy	8,704 +200	+2%	+$17.6K	0.03%	102
2018 Q3	$804K	Hold	8,504	–	–	0.03%	125
2018 Q2	$788K	Hold	8,504	–	–	0.03%	115
2018 Q1	$805K	Hold	8,504	–	–	0.03%	106
2017 Q4	$822K	Sell	8,504 -1,039	-11%	-$97.9K	0.04%	104
2017 Q3	$848K	Buy	9,543 +1,039	+12%	+$79.1K	0.04%	112
2017 Q2	$617K	Buy	8,504 +17	+0.2%	+$1.14K	0.03%	136
2017 Q1	$553K	Hold	8,487	–	–	0.03%	136
2016 Q4	$531K	Hold	8,487	–	–	0.03%	141
2016 Q3	$535K	Hold	8,487	–	–	0.03%	128
2016 Q2	$525K	Sell	8,487 -60	-0.7%	-$3.66K	0.04%	131
2016 Q1	$488K	Hold	8,547	–	–	0.04%	133
2015 Q4	$506K	Hold	8,547	–	–	0.04%	126
2015 Q3	$465K	Sell	8,547 -4,788	-36%	-$312K	0.04%	140
2015 Q2	$896K	Buy	13,335 +4,727	+55%	+$309K	0.09%	106
2015 Q1	$504K	Sell	8,608 -623	-7%	-$37.6K	0.04%	146
2014 Q4	$604K	Sell	9,231 -1,195	-11%	-$75.3K	0.05%	121
2014 Q3	$602K	Buy	+10,426	New	+$579K	0.05%	111

Other funds holding ABBV

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return

Norges Bank Oslo, Norway $1T AUM

Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return

Allen Investment Management's ABBV Position: Q2 2026 in Review

Allen Investment Management reduced its AbbVie (ABBV) stake by 0.53% in Q2 2026, selling an estimated $16.1K and leaving 13,993 shares worth $3.52M. The position accounts for 0.04% of the portfolio, ranked #115.

Allen Investment Management first reported a position in ABBV in Q3 2014 and has held it in 48 quarters since. 4,195 funds tracked by Wall St. Rank hold ABBV as of Q2 2026.

Allen Investment Management held 13,993 shares of AbbVie worth $3.52M as of Q2 2026.
Allen Investment Management sold 75 AbbVie shares in Q2 2026, an estimated $16.1K.
AbbVie made up 0.04% of Allen Investment Management's portfolio in Q2 2026, its #115 holding.
Allen Investment Management first reported a position in AbbVie in Q3 2014 and has held it in 48 quarters since.
4,195 funds tracked by Wall St. Rank held AbbVie as of Q2 2026.

Based on Allen Investment Management's 13F filing for Q2 2026, filed 5 Aug 2026.